What is the difference between semaglutide and tirzepatide?
Tirzepatide activates two gut-hormone receptors (GIP and GLP-1); semaglutide activates one (GLP-1). Semaglutide is made by Novo Nordisk and sold as Ozempic and Rybelsus for type 2 diabetes and Wegovy for weight loss. Tirzepatide is made by Eli Lilly and sold as Mounjaro for type 2 diabetes and Zepbound for weight loss. Both are once-weekly injections. That second receptor is the main reason tirzepatide tends to produce more weight loss.
Tirzepatide vs semaglutide: which one loses more weight?
Tirzepatide, consistently. In the SURMOUNT-5 head-to-head trial, tirzepatide averaged 20.2% body-weight loss versus 13.7% for semaglutide. A February 2026 network meta-analysis of 28 randomized trials and 34,367 participants found tirzepatide produced 6.10% greater percentage weight loss and 4.55 kg more absolute weight loss at each drug's maximum approved dose. Earlier meta-analyses put the average gap at roughly 4.23 kg, widening to about 6.5 kg above 10 mg.
Read the full comparison →
Is tirzepatide better than semaglutide?
It depends which outcome matters most to you. Tirzepatide wins clearly on weight loss and on blood-sugar control. On heart protection the picture reverses or evens out: a 2026 real-world study of 21,250 patients with existing cardiovascular disease (STEER) linked semaglutide to 29% fewer major cardiac events, while a separate 172,382-patient claims analysis in type 2 diabetes found one-year event rates identical (1.3% versus 1.3%). Many of these comparisons are funded by one manufacturer or the other.
What is the difference between tirzepatide and Ozempic?
Ozempic is a brand name for semaglutide, so this is really the tirzepatide versus semaglutide question. Ozempic is approved only for type 2 diabetes and tops out at 2 mg weekly; the weight-loss version of the same molecule is Wegovy, dosed to 2.4 mg. Tirzepatide is a different molecule entirely, sold as Mounjaro for diabetes and Zepbound for weight loss, and dosed up to 15 mg weekly.
Tirzepatide vs Ozempic for weight loss: which is better?
Tirzepatide. Compared with semaglutide at full weight-loss dosing, tirzepatide averaged 20.2% body-weight loss versus 13.7% in the SURMOUNT-5 head-to-head trial. Ozempic specifically is dosed for diabetes and stops at 2 mg, so it generally produces less weight loss than Wegovy, the 2.4 mg version of the same drug. Ozempic is not FDA-approved for weight management.
Which lowers blood sugar more, tirzepatide or semaglutide?
Tirzepatide, by a modest margin. A February 2026 network meta-analysis of 28 randomized trials comparing the two at FDA-approved maximum doses found HbA1c 0.33 percentage points lower on tirzepatide. Both produce large reductions in HbA1c, and for most people the difference between them is smaller than the difference either one makes versus no treatment.
Semaglutide or tirzepatide: which protects the heart more?
Unresolved. The STEER study (2026, 21,250 propensity-matched patients with cardiovascular disease but no diabetes) found 29% fewer 3-point MACE on semaglutide (HR 0.71) — but it is observational, and every author is an employee or shareholder of Novo Nordisk, semaglutide's maker. A 172,382-patient target-trial-emulation study in type 2 diabetes found the two comparable (1.3% versus 1.3% one-year MACE, HR 1.06). Semaglutide holds an FDA cardiovascular-risk-reduction label; tirzepatide's outcomes trial, SURPASS-CVOT, compared it against dulaglutide rather than placebo.
Read the full analysis →
Which has fewer side effects, semaglutide or tirzepatide?
Neither has a clear advantage. Both cause the same gastrointestinal profile — nausea, vomiting, diarrhea, constipation — worst during dose escalation. Label rates come from separate trials and are not directly comparable, but Wegovy reports nausea in 44% of users versus 25% to 29% for Zepbound. One FDA pharmacovigilance analysis of 133,872 reports found acute kidney injury reported 2.3 times more often for semaglutide (1.07%) than tirzepatide (0.47%). Tolerability is highly individual.
Do semaglutide and tirzepatide cause the same amount of muscle loss?
Broadly yes, and they are the two heaviest in the class. A 2025 network meta-analysis of 22 trials and 2,258 patients found GLP-1 medicines cost about 0.86 kg of lean mass on average, roughly 24% of total weight lost, with tirzepatide 15 mg and semaglutide 2.4 mg producing the largest lean-mass reductions. Adequate protein and resistance training are the main countermeasures.
See the muscle-loss data →
Can you switch from semaglutide to tirzepatide?
Yes, and it is common, but there is no published dose-equivalence chart between the two drugs. Clinicians restart tirzepatide at the lowest dose, 2.5 mg weekly, and titrate upward regardless of the semaglutide dose you were taking, so the nausea ramp usually returns. Switching should be done under medical supervision.
Are semaglutide and tirzepatide approved for the same conditions?
No. Semaglutide carries an FDA label for reducing major cardiovascular events and has kidney-outcome evidence in diabetic kidney disease from the FLOW trial. Tirzepatide (Zepbound) is the only one approved for moderate-to-severe obstructive sleep apnea with obesity, granted in December 2024, and reduced a composite kidney outcome by 23% versus dulaglutide in SURPASS-CVOT. Both are approved for type 2 diabetes and chronic weight management under their respective brand names.
See the kidney data →
Which costs more, semaglutide or tirzepatide?
They are priced in the same range. US list prices run roughly $1,000 to $1,500 per month for both, with Ozempic around $970 cash, and neither has an FDA-approved generic. What you actually pay depends far more on insurance, manufacturer savings programs, and pharmacy channel than on which drug you choose. From July 1, 2026, Medicare coverage for obesity caps out-of-pocket cost near $50 per month for eligible patients. Prices and programs change often — verify current terms.